Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Observes patients with recurrent or spreading prostate cancer over the long term

Records treatment and disease course in adults with returning or spreading prostate cancer.

Plain-language title generated from the registry record
Registry title: PROCARE - PROstate Cancer Real World Evidence Registry

Key facts

Where
Aachen, Augsburg, Bayenthal, Bayreuth, Bergisch Gladbach, Berlin, Bonn, Braunschweig, Dessau, Duisburg, Düsseldorf, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Giessen, Halle, Hamburg, Heidelberg, Herne, Herzberg am Harz, Hildesheim, Jena, Karlsruhe, Kempten (Allgäu), Leipzig, Lübeck, Magdeburg, Mannheim, Marburg, Neunkirchen, Neustadt am Rübenberge, Nuremberg, Nürtingen, Paderborn, Regensburg, Rostock, Trier, Tübingen, Ulm, Wetzlar, Wilhelmshaven, Wuppertal, Würselen, and Würzburg, GermanySee the 52 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry follows adult men with prostate cancer that has come back or spread, who are about to start a new systemic treatment. Patients are observed over a long period.

Age
18 years or older
Sex
Men only
Disease stage
Prostate cancer in one of four groups: PSA coming back after local treatment; non-metastatic castration-resistant; metastatic hormone-sensitive; or metastatic castration-resistant.
Earlier treatment
For the PSA-recurrence, non-metastatic and metastatic hormone-sensitive groups, earlier local treatment (surgery or radiotherapy) has not worked or cannot be repeated, or the patient declines it. Patients start a new line of systemic therapy at entry or within 4 weeks after.

Main reasons for not taking part

  • Severe other illnesses that make follow-up not possible, according to the treating doctor
  • Not available for follow-up, according to the treating doctor
  • Patient cannot or will not sign the consent form

Read by machine on 12 November 2026.

Where in Germany

  • University Hospital AachenAachen, GermanyContact: Matthias Saar, ProfessorTaking people
  • University Hospital AugsburgAugsburg, GermanyContact: Julie Steinestel, MDTaking people
  • Medical Office for UrologyBayenthal, GermanyContact: Jörg Klier, MDTaking people
  • Hospital Bayreuth GmbHBayreuth, GermanyContact: Alexander Kiani, ProfessorTaking people
  • Marien Hospital Bergisch Gladbach,Bergisch Gladbach, GermanyContact: Stephan Machtens, MDTaking people
  • "Vivantes Prostatazentrum" Hospital "am Urban"Berlin, GermanyContact: Jonas Busch, ProfessorTaking people
  • Johanniter GmbH, JohanniterkrankenhausBonn, GermanyContact: Carsten Ohlmann, ProfessorTaking people
  • Johanniter Hosptal BonnBonn, GermanyContact: Carsten Ohlmann, ProfessorTaking people
  • University Hospital BonnBonn, GermanyContact: Jörg Ellinger, ProfessorTaking people
  • Medical Office for UrologyBraunschweig, GermanyContact: Harald Junius, MDTaking people
  • City Hospital DessauDessau, GermanyContact: Frank-Stefan SailerTaking people
  • Medical Office for Urology "Urologicum"Duisburg, GermanyContact: Eva Hellmis, MDTaking people
  • University Hospital DüsseldorfDüsseldorf, GermanyContact: Günther Niegisch, ProfessorTaking people
  • University Hospital ErlangenErlangen, GermanyContact: Peter J. Goebell, ProfessorTaking people
  • University Hospital EssenEssen, GermanyContact: Boris Hadaschik, ProfessorTaking people
  • University Hospital Frankfurt/MainFrankfurt am Main, GermanyContact: Chun, ProfessorTaking people
  • Universitätsklinikum FreiburgFreiburg im Breisgau, GermanyContact: Christian Gratzke, ProfessorTaking people
  • Universitiy Hospital Gießen und Marburg GmbH, Site: GießenGiessen, GermanyContact: Florian Wagenlehner, ProfessorTaking people
  • Universitiy Hospital HalleHalle, GermanyContact: Georgios Gakis, ProfessorTaking people
  • University Hospital HalleHalle, GermanyContact: Georgios Gakis, ProfessorTaking people
  • University hospital Hamburg EppendorfHamburg, GermanyContact: Gunhild von Amsberg, ProfessorTaking people
  • National Center for Tumor Dieseases (NCT) HeidelbergHeidelberg, GermanyContact: Stefanie Zschäbitz, MDTaking people
  • Marien Hospital Herne, University Hospital der Ruhr-Universität BochumHerne, GermanyContact: Florian Roghmann, MDTaking people
  • Medical Office for UrologyHerzberg am Harz, GermanyContact: Thorsten Werner, MDTaking people
  • St. Bernward Hospital HildesheimHildesheim, GermanyContact: Ulrich Kaiser, ProfessorTaking people
  • St. Bernward Krankenhaus GmbHHildesheim, GermanyContact: Ulrich Kaiser, ProfessorTaking people
  • University Hospital JenaJena, GermanyContact: Marc-Oliver Grimm, ProfessorTaking people
  • Urban Hospital KarlsruheKarlsruhe, GermanyContact: Dogu Teber, ProfessorTaking people
  • Hospital KemptenKempten (Allgäu), GermanyContact: Stephan Tschirdewahn, MDTaking people
  • University Hospital LeipzigLeipzig, GermanyContact: Jens Uwe Stolzenburg, MDTaking people
  • Univerity Hospital Schleswig-HolsteinLübeck, GermanyContact: Axel Merseburger, ProfessorTaking people
  • Medical Office for Urology Altstadtquartier MagdeburgMagdeburg, GermanyContact: Nils Kröger, MDTaking people
  • University Hospital MagdeburgMagdeburg, GermanyContact: Schostak Martin, ProfessorTaking people
  • Urologie Altstadtquartier MagdeburgMagdeburg, GermanyContact: Nils Kröger, MDTaking people
  • University Hospital MannheimMannheim, GermanyContact: Karl Kowalewski, ProfessorTaking people
  • Universital Hospital Gießen & Marburg GmbH, Site: MarburgMarburg, GermanyContact: Christer Groeben, MDTaking people
  • Center for Urology BoxbergNeunkirchen, GermanyContact: Frank Becker, MDTaking people
  • MVZ Onco Medical GmbH NeustadtNeustadt am Rübenberge, GermanyContact: Munir Rababah, MDTaking people
  • Hospital Nürnberg NorthNuremberg, GermanyContact: Marinela Augustin, MDTaking people
  • Medical Office for Urology NürtingenNürtingen, GermanyContact: Tilman Todenhöfer, ProfessorTaking people
  • Studienpraxis UrologieNürtingen, GermanyContact: Tillmann Todenhöfer, Professor MDTaking people
  • "Brüder" Hospital St. Joseph PaderbornPaderborn, GermanyContact: Harald Müller-Huesmann, MDTaking people
  • Caritas Hospital St. JosefRegensburg, GermanyContact: Marco Schnabel, ProfessorTaking people
  • University hospital RostockRostock, GermanyContact: Angelika Borkewetz, ProfessorTaking people
  • Hospital "Barmherzigen Brüder "TrierTrier, GermanyContact: Neisius AndreasTaking people
  • University Hospital TübingenTübingen, GermanyContact: Steffen Rausch, ProfessorTaking people
  • University Hospital UlmUlm, GermanyContact: Friedemann Zengerling, MDTaking people
  • Hospital WetzlarWetzlar, GermanyContact: Victor Galonda, MDTaking people
  • Praxisgemeinschaft f. Onkologie & UrologieWilhelmshaven, GermanyContact: Gerald Rodemer, MDTaking people
  • University Hospital WuppertalWuppertal, GermanyContact: Stephan Degener, ProfessorTaking people
  • Medical Office for UrologyWürselen, GermanyContact: Thomas Pulte, MDTaking people
  • University Hospital WürzburgWürzburg, GermanyContact: Hubert Kübler, ProfessorTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
UroTrials Company (GmbH)
Trial code
NCT06835218
Record updated
12 March 2026
Original description
The aim of this registry study with long-term follow-up is to record the course of therapy and disease in patients with recurrent and metastatic prostate cancer. The following patient groups are planned:Read full original descriptionShow less

PROstate CAncer Real World Evidence Registry: RECURRENT AND METASTATIC PROSTATE CANCER

The aim of this registry study with long-term follow-up is to record the course of therapy and disease in patients with recurrent and metastatic prostate cancer. The following patient groups are planned:

* Patients with a recurrence of PSA after surgical removal or radiation of the prostate due to prostate cancer; so-called PSA recurrence (relapse) or biochemical recurrence. * Patients with a PSA recurrence who have received treatment by hormone deprivation therapy (so-called androgen deprivation) and in whom the PSA value has nevertheless risen again without spreading to other organs or parts of the body, so-called non-metastatic castration-resistant prostate cancer. * Patients with proven spread to other organs or parts of the body (= metastases, e.g. in the bone) without hormone deprivation therapy having been initiated, so-called metastatic hormone-sensitive prostate cancer. * Patients with prostate cancer and spread to other organs or parts of the body (= metastases) in whom the tumor disease has progressed despite hormone withdrawal treatment (e.g. as evidenced by an increase in PSA), so-called metastatic castration-refractory prostate cancer.

These four groups of patients are enrolled and observed independently of each other at different time periods.

Inclusion: Adult prostate cancer patients (age ≥18 years); Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line); Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, … line); For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient; Patients, who are able and willing to sign the informed consent form.

Exclusion: Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician.

ClinicalTrials.gov NCT06835218